Access cutting-edge breast cancer treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access breast cancer specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related breast cancer treatment provided free
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Sponsor: Relay Therapeutics, Inc.
Check if you qualify for this breast cancer clinical trial in Palo Alto, CA
If you're searching for breast cancer treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.